CF PharmTech, Inc.
2652.HK
Hong Kong Stock Exchange17.50
HKD
-0.90
- -
ISIN
CNE1000074R9
Return %
Stock
S&P500
1Y
-54.55
21.04
3Y
-54.55
71.31
5Y
-54.55
72.92
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Liang Wenqing
- Full Time Employees
- 557
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- No. 16, Hucundang Road Suzhou People's Republic of China 215143
- IPO Date
- Oct 8, 2025
- Website
- cfpharmtech.com
- Similar Companies
- Business
- CF PharmTech, Inc.長風藥業股份有限公司 is a global innovator in inhalation drug delivery technology, focused on developing and commercializing complex inhalation formulations and associated delivery systems. The company positions itself as a platform-based pharmaceutical developer and contract development and manufacturing organization (CDMO) with integrated capabilities spanning device engineering, precision drug delivery, formulation science, process development, CMC scale-up, regulatory strategy and filings, and commercialization support for global markets. Primary activities include development of inhalation products for respiratory diseases, such as asthma and COPD, through metered-dose inhalers, inhalation powders, nasal spray concepts, and related delivery devices; formulation optimization; preclinical studies; clinical development support including IND preparation; and manufacturing and packaging of inhalation products at scale. Geographically, CF PharmTech operates with a global reach, pursuing development and commercialization across major markets including China, the United States, Europe, and additional regions in Southeast Asia and South America, with an emphasis on meeting international regulatory requirements and obtaining multiple product registrations. The company maintains research and development, manufacturing, and regulatory capabilities aimed at accelerating asset progression from discovery through to regulatory approval and commercial launch. Headquarters are located in Frankfurt am Main, Germany, with substantive operations described in Chinese and international market disclosures, reflecting its multinational focus and cross-border collaboration model. Founded in 2010, CF PharmTech emphasizes building a diversified portfolio of inhalation products and platform technologies designed to address high-barrier-to-entry respiratory therapies, leveraging its device engineering, lung-targeted delivery systems, and integrated CMC capabilities to support clients and partners in delivering novel inhaled therapies. The company reports strategic initiatives to broaden its product candidate slate, expand overseas regulatory filings, and pursue at least several new product approvals and commercial launches within the 2026–2030 timeframe, reinforcing its commitment to growing as a globally recognized inhalation drug delivery platform company. In addition to its core inhalation programs, CF PharmTech collaborates with research entities and pharmaceutical partners to accelerate development timelines, optimize delivery performance, and expand its market access through licensing and partnership arrangements.